Abstract

Methods for evaluating drugs to ensure there is value for money spent have been debated for years. There have been many attempts at controlling the use of drugs starting with formularies, limited listings for specific uses and the negotiation of prices. The strategy put forward by the lead authors would be helpful to all parties. Their proposal would allow evidence to be the arbiter and provide information that is understood by all concerned. It would take courage by all interested parties to accept these ideas. However, the time is right for the adoption of a better way to keep drug programs affordable without denying anyone the treatments that can make a difference to their health.